Cargando…

Molecular targets of Chinese herbs: a clinical study of metastatic colorectal cancer based on network pharmacology

Increasing evidence has shown that Chinese herbal medicine (CHM) has promising therapeutic effects in colorectal cancer (CRC); however, the active ingredients and potential targets remain unclear. In this study, we aimed to investigate the relative molecular targets of the Chinese herbs that have be...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Hongxu, Hao, Jian, Niu, Yangyang, Liu, Dan, Chen, Dan, Wu, Xiongzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940835/
https://www.ncbi.nlm.nih.gov/pubmed/29740162
http://dx.doi.org/10.1038/s41598-018-25500-x
_version_ 1783321167274180608
author Zhu, Hongxu
Hao, Jian
Niu, Yangyang
Liu, Dan
Chen, Dan
Wu, Xiongzhi
author_facet Zhu, Hongxu
Hao, Jian
Niu, Yangyang
Liu, Dan
Chen, Dan
Wu, Xiongzhi
author_sort Zhu, Hongxu
collection PubMed
description Increasing evidence has shown that Chinese herbal medicine (CHM) has promising therapeutic effects in colorectal cancer (CRC); however, the active ingredients and potential targets remain unclear. In this study, we aimed to investigate the relative molecular targets of the Chinese herbs that have been found effective in treating metastatic CRC (mCRC) based on clinical data and network pharmacology. In multivariate analysis CHM resulted an independent prognostic factor. The hazard ratio was 0.103 (95% confidence interval = 0.064–0.164; P < 0.001). Compared with the non-CHM group, the median survival time of the CHM group was also improved (40 versus 12 months; P < 0.001). Eighteen out of 295 herbs showed significant correlation with survival results (P < 0.05). Bioinformatics analysis indicated that the 18 herbs realize anti-CRC activity mainly through suppressing the proliferative activity of ERBB2, peroxisome proliferator-activated receptor gamma, and retinoid X receptor, suppressing angiogenesis via inhibition of VEGFR and VEGFA expression, inhibiting the phosphatidylinositol-3-kinase/AKT1 signaling pathway directly through SRC and AKT1, and reducing tumor necrosis factor-induced inflammation.
format Online
Article
Text
id pubmed-5940835
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-59408352018-05-11 Molecular targets of Chinese herbs: a clinical study of metastatic colorectal cancer based on network pharmacology Zhu, Hongxu Hao, Jian Niu, Yangyang Liu, Dan Chen, Dan Wu, Xiongzhi Sci Rep Article Increasing evidence has shown that Chinese herbal medicine (CHM) has promising therapeutic effects in colorectal cancer (CRC); however, the active ingredients and potential targets remain unclear. In this study, we aimed to investigate the relative molecular targets of the Chinese herbs that have been found effective in treating metastatic CRC (mCRC) based on clinical data and network pharmacology. In multivariate analysis CHM resulted an independent prognostic factor. The hazard ratio was 0.103 (95% confidence interval = 0.064–0.164; P < 0.001). Compared with the non-CHM group, the median survival time of the CHM group was also improved (40 versus 12 months; P < 0.001). Eighteen out of 295 herbs showed significant correlation with survival results (P < 0.05). Bioinformatics analysis indicated that the 18 herbs realize anti-CRC activity mainly through suppressing the proliferative activity of ERBB2, peroxisome proliferator-activated receptor gamma, and retinoid X receptor, suppressing angiogenesis via inhibition of VEGFR and VEGFA expression, inhibiting the phosphatidylinositol-3-kinase/AKT1 signaling pathway directly through SRC and AKT1, and reducing tumor necrosis factor-induced inflammation. Nature Publishing Group UK 2018-05-08 /pmc/articles/PMC5940835/ /pubmed/29740162 http://dx.doi.org/10.1038/s41598-018-25500-x Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Zhu, Hongxu
Hao, Jian
Niu, Yangyang
Liu, Dan
Chen, Dan
Wu, Xiongzhi
Molecular targets of Chinese herbs: a clinical study of metastatic colorectal cancer based on network pharmacology
title Molecular targets of Chinese herbs: a clinical study of metastatic colorectal cancer based on network pharmacology
title_full Molecular targets of Chinese herbs: a clinical study of metastatic colorectal cancer based on network pharmacology
title_fullStr Molecular targets of Chinese herbs: a clinical study of metastatic colorectal cancer based on network pharmacology
title_full_unstemmed Molecular targets of Chinese herbs: a clinical study of metastatic colorectal cancer based on network pharmacology
title_short Molecular targets of Chinese herbs: a clinical study of metastatic colorectal cancer based on network pharmacology
title_sort molecular targets of chinese herbs: a clinical study of metastatic colorectal cancer based on network pharmacology
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940835/
https://www.ncbi.nlm.nih.gov/pubmed/29740162
http://dx.doi.org/10.1038/s41598-018-25500-x
work_keys_str_mv AT zhuhongxu moleculartargetsofchineseherbsaclinicalstudyofmetastaticcolorectalcancerbasedonnetworkpharmacology
AT haojian moleculartargetsofchineseherbsaclinicalstudyofmetastaticcolorectalcancerbasedonnetworkpharmacology
AT niuyangyang moleculartargetsofchineseherbsaclinicalstudyofmetastaticcolorectalcancerbasedonnetworkpharmacology
AT liudan moleculartargetsofchineseherbsaclinicalstudyofmetastaticcolorectalcancerbasedonnetworkpharmacology
AT chendan moleculartargetsofchineseherbsaclinicalstudyofmetastaticcolorectalcancerbasedonnetworkpharmacology
AT wuxiongzhi moleculartargetsofchineseherbsaclinicalstudyofmetastaticcolorectalcancerbasedonnetworkpharmacology